Effect of the novel anti-NGF monoclonal antibody DS002 on the metabolomics of pain mediators, cartilage and bone

The anti-nerve growth factor antibody class of drugs interrupts signaling by blocking NGF binding to TrkA receptors for the treatment of pain; however, this target class of drugs has been associated with serious adverse effects in the joints during clinical trials. DS002 is a novel anti-nerve growth...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Frontiers in Pharmacology
المؤلفون الرئيسيون:	Dandan Jin, Haoyi Yang, Zhiyou Chen, Yuxin Hong, Hehua Ma, Zhenzhen Xu, Bei Cao, Fei Fei, Yuwen Zhang, Weitao Wu, Lei Tang, Runbin Sun, Chunhe Wang, Juan Li
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Frontiers Media S.A. 2024-08-01
الموضوعات:	metabolomics pain aromatic amino acids biomarkers anti-ngf drugs
الوصول للمادة أونلاين:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1396790/full